Bemdaneprocel

贝尼乐赛

Report date: 2025/06/13 11:41:36

Base Information

Drug NameBemdaneprocel
Drug Alias NamePluripotent stem cell derived dopaminergic neuronsBRT-DA01DA-01MSK-DA01
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Source of cells > Embryonic stem cell-derivedCell and gene therapy > Cell therapy > Somatic cell > Dopaminergic neural orogenitor cell therapy
Mechanisms of ActionStem cell replacementsDopaminergic cell replacements
TargetsNot applicable
Therapy Area/IndicationsParkinson Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesAustralia
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesBluerock Therapeutics Lp
China Registration ClassN/A

Develop Information

Active CompaniesBluerock Therapeutics Gp LlcBluerock Therapeutics LpBayer AG
Inactive CompaniesN/A
Active IndicationsParkinson Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A